https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/women

The Latest

solving maze

This Week in HIV Research: Solving the Riddle of Poor PrEP Uptake

July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.

By Barbara Jungwirth and Myles Helfand
injectable

What Are the New HIV Treatment and Prevention Drugs Under Development in 2020?

Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.

By Terri Wilder, M.S.W.
links in chain

This Week in HIV Research: Links in a Chain

July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?

By Barbara Jungwirth and Myles Helfand
Vaccination being filled

Investigational PrEP Injection, Dosed Every Other Month, Beats Daily PrEP in Phase 3 Study

New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.

By Kenyon Farrow
Lynne Mofenson

After Years of Decline, Perinatal HIV Transmission Has Hit a Plateau. Why?

This researcher has some ideas about what we need to do to address the problem.

By Terri Wilder, M.S.W.
cisgender woman prescription

Evaluating PrEP Uptake and Adherence in Cisgender Women—and What to Do About It

Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.

By Terri Wilder, M.S.W.
data

This Week in HIV Research: There’s No Such Thing as Too Much Data

May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.

By Barbara Jungwirth and Myles Helfand
fast pace of life

This Week in HIV Research: Special Considerations

April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.

By Barbara Jungwirth and Myles Helfand
Senior woman receives prescription medication from doctor

Should All PrEP Users on Truvada Switch to Descovy? These Leading Docs Say, ‘Not So Fast.’

Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.

By Larry Buhl
long winding road through countryside

This Week in HIV Research: The Long Road to the End

Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.

By Barbara Jungwirth and Myles Helfand